MedGenome Labs Limited

MedGenome Labs Limited is a biotechnology company specializing in genomics and precision medicine, offering a range of advanced genomic sequencing and bioinformatics solutions to enhance health outcomes globally. MedGenome Labs Limited, founded in 2013 and headquartered in Bangalore, India, focuses on genomics to improve precision medicine. The company has completed a total of 12 funding deals, with the most recent funding round being Series E. Vedam Ramprasad is the CEO of the company.

MedGenome Labs Limited specializes in sequencing services that include whole genome sequencing (WGS), whole exome sequencing (WES), RNA sequencing, single-cell sequencing, and immune repertoire sequencing. The company utilizes advanced technologies and AI-driven bioinformatics to convert complex biological data into actionable insights, thereby supporting drug development and diagnostics. Their clientele comprises leading academic institutions, biopharmaceutical companies, clinical diagnostic laboratories, and contract research organizations across North America, Europe, Asia, and Latin America, focusing on therapeutic areas such as oncology, immunology, rare diseases, and neurology. In the most recent fiscal year 2023, MedGenome Labs Limited recorded a revenue of USD 30.

44 mn, with an EBITDA of USD -1. 58 mn. MedGenome Labs Limited plans to utilize the USD 50 mn raised in Series D funding to expand its market presence and enhance product development in genetic testing, contributing to the global genomic dataset. In July 2025, MedGenome Labs Limited raised INR 4 billion in series E funding led by Maj Invest and Novo Holdings, with participation from Sofina.

MedGenome Labs Limited will use the July 2025 funding to expand access to its genomics and diagnostic services in India and other emerging markets.